BioXcel Therapeutics
BTAI
73 hedge funds and large institutions have $27.6M invested in BioXcel Therapeutics in 2023 Q4 according to their latest regulatory filings, with 12 funds opening new positions, 22 increasing their positions, 28 reducing their positions, and 24 closing their positions.
7% more capital invested
Capital invested by funds: $25.8M → $27.6M (+$1.75M)
0.18% less ownership
Funds ownership: 2.18% → 2% (-0.18%)
14% less funds holding
Funds holding: 85 → 73 (-12)
21% less repeat investments, than reductions
Existing positions increased: 22 | Existing positions reduced: 28
49% less call options, than puts
Call options by funds: $776K | Put options by funds: $1.51M
50% less first-time investments, than exits
New positions opened: 12 | Existing positions closed: 24
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Adage Capital Partners
Boston,
Massachusetts
|
+$922K |
| 2 |
AWA
Arete Wealth Advisors
Chicago,
Illinois
|
+$379K |
| 3 |
PI
Pennant Investors
Summit,
New Jersey
|
+$292K |
| 4 |
BlackRock
New York
|
+$266K |
| 5 |
VF
Virtu Financial
New York
|
+$207K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Two Sigma Investments
New York
|
-$1.09M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$633K |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
-$455K |
| 4 |
Ameriprise
Minneapolis,
Minnesota
|
-$442K |
| 5 |
Goldman Sachs
New York
|
-$395K |
BTAI Hedge Fund Activity: Q4 2023 in Review
73 of the 6,869 institutional investors tracked by Wall St. Rank reported a position in BioXcel Therapeutics (BTAI) for Q4 2023, worth a combined $27.6M — up 6.8% from $25.8M a quarter earlier.
Sellers outnumbered buyers: 24 funds closed out of BTAI and 12 opened new positions — a net loss of 12 holders — while 28 trimmed existing stakes and 22 added.
The largest buyer was Adage Capital Partners, adding an estimated $922K. The largest seller was Two Sigma Investments, exiting entirely with an estimated $1.09M sold.
- 73 institutional investors held BioXcel Therapeutics (BTAI) as of Q4 2023, down from 85 in Q3 2023.
- Funds reported $27.6M of BioXcel Therapeutics stock for Q4 2023, up 6.8% quarter-over-quarter.
- 12 funds opened new BioXcel Therapeutics positions in Q4 2023 and 24 closed out, a net change of -12 holders.
- The largest BioXcel Therapeutics buyer in Q4 2023 was Adage Capital Partners, an estimated $922K added.
- The largest BioXcel Therapeutics seller in Q4 2023 was Two Sigma Investments, an estimated $1.09M sold.
Based on aggregated 13F filings for Q4 2023.